Research Article

Immunology and Cell Biology (2006) 84, 6–12; doi:10.1111/j.1440-1711.2005.01388.x

Activators of the energy sensing kinase AMPK inhibit random cell movement and chemotaxis in U937 cells

John Kanellis1,2,3, Rangi K Kandane3, Dariush Etemadmoghadam3, Scott A Fraser2,3, Peter F Mount1,2,3, Vicki Levidiotis1,2,3, Bruce E Kemp4 and David A Power1,3

  1. 1 Department of Nephrology, Austin Hospital, Victoria, Australia
  2. 2 Department of Medicine, The University of Melbourne, Austin Hospital, Victoria, Australia
  3. 3 Austin Research Institute, Victoria, Australia
  4. 4 CSIRO Health Sciences and Nutrition, Melbourne, Victoria, Australia

Correspondence: Professor David A Power, Department of Nephrology, Austin Hospital, Heidelberg, Vic. 3084, Australia. Email: david.power@austin.org.au

Received 6 May 2005; Accepted 27 June 2005; Published online 19 December 2005.

Top

Abstract

AMP-activated protein kinase (AMPK) is a key energy sensor, known to regulate energy metabolism in diverse cell types. Hypoxia is encountered frequently in the microenvironments of inflammatory lesions and is a critical regulator of function in inflammatory cells. Energy deficiency is one of the consequences of hypoxia, but its potential role in modulating leucocyte function has received little attention. Using micropore chemotaxis assays to assess migratory responses of the monocyte-like cell line U937, it was found that the AMPK activators AICAR and phenformin rapidly reduced random migration (chemokinesis) as well as chemotaxis due to stromal cell-derived factor (SDF)1alpha. There was an approximate 50% reduction in both chemokinesis and chemotaxis following 30 min preincubation with both AICAR and phenformin (P < 0.01), and this continued with up to 24 h preincubation. The binding of SDF1alpha to its receptor CXCR4 was unaltered, suggesting AMPK was acting on downstream intracellular signalling pathways important in cell migration. As AMPK and statins are known to inhibit HMG CoA reductase, and both reduce cell migration, the effect of mevastatin on U937 cells was compared with AMPK activators. Mevastatin inhibited cell migration but required 24 h preincubation. As expected, the inhibitory effect of mevastatin was associated with altered subcellular localization of the Rho GTPases, RhoA and cdc42, indicating decreased prenylation of these molecules. Although the effect of AMPK activation was partially reversed by mevalonate, this was not associated with altered subcellular localization of Rho GTPases. The data suggest that activation of AMPK has a general effect on cell movement in U937 cells, and this is not due to inhibition of HMG CoA reductase. These are the first data to show an effect of AMPK on cell movement, and suggest a fundamental role for energy deficiency in regulating cellular behaviour.

Keywords:

chemokine, chemotaxis, inflammation, monocyte, macrophage

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Statins: lower lipids and better bones?

Nature Medicine News and Views (01 Jan 2000)

Ways of coping with stress

Nature News and Views (25 Aug 1994)

See all 3 matches for News And Views

Extra navigation

.
ADVERTISEMENT